about
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesEuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicineGenes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocolsMinimal Residual Disease Assessment in the Context of Multiple Myeloma TreatmentMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesPrognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemiaNew criteria for response assessment: role of minimal residual disease in multiple myelomaGenome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemiaEvaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia.Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemiaDetection of human tumor cells by amplicon fusion site polymerase chain reaction (AFS-PCR).Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.Determination of minimal residual disease in leukaemia patients.Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.Immunophenotyping of acute leukemias and myelodysplastic syndromes.Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia.A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemiaTime point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemiaMonitoring of minimal residual disease in leukemia, advantages and pitfalls.Methods of minimal residual disease (MRD) detection in childhood haematological malignancies.Progress of minimal residual disease studies in childhood acute leukemia.Minimal residual disease in acute lymphoblastic leukemiaSignificance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective reviewStatus of minimal residual disease testing in childhood haematological malignanciesMinimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology groupRole of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.Minimal residual disease quantitation in acute myeloid leukemiaERK/Drp1-dependent mitochondrial fission is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells.Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group.Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
P2860
Q24604581-E08E32D6-CD32-499D-8911-7A00577D00BFQ24605023-5612AC5A-04B0-4FF8-B7B0-AFB0ABD0C9E8Q24685514-B47BACB5-EE7B-4844-87A0-CAF09C8459C4Q24685883-046D9015-33CD-4DD8-B4C1-FCC42F87047AQ26768653-B5511BD2-3280-45CB-8122-BFAFCE4CD781Q26828511-D1F4917B-CA57-43BB-80A5-75F14755548FQ27006773-325E900C-50AA-4C26-B1F6-DE9A4B3F9478Q27027512-12110440-0ED3-46D7-8C47-4D5F030E0BBFQ28943308-3FE8949D-DFF9-477F-9C4C-C634D6B965ACQ33889952-89A5D9C1-10F1-4D4C-88E7-F22B7DA911EAQ33931882-A16C9425-B79E-46B8-A071-48D08BB74F9BQ34449151-157AF264-D742-45FF-AF3D-12C884934F1CQ34519922-0A56A0A8-2F65-4DC5-AE43-96AAEA9C64EBQ35134983-165BC107-DFAD-4662-B30F-DBF0D2111A48Q35145184-9C35176F-031F-4363-B86B-F22711C159CAQ35561038-A795ECF1-AFB2-4AC6-B256-EFF5155EDA32Q35679885-3FA0F02D-4B13-4F5E-85AC-B527B87EBD78Q35712192-48BBAE8F-0074-473B-A353-7E38FB54B16DQ35849791-9B1252C3-2412-44C5-A767-27D3BA105F6FQ35853569-DE881DB4-B318-4919-BE38-240AFA7187C5Q35925051-EB414F08-D5AF-4C04-AD49-91A561FFF086Q36366977-B17563AD-6EE4-4FBD-A046-A878C56461EBQ36410862-83563F1F-2332-481C-9969-69FDD3EDCE30Q36652555-AD8CA991-F620-4C2E-9A60-EBDA319EA6CBQ36726108-124210E5-0CC3-432B-A757-A49FAFEEF08BQ36981845-6D41CDD8-FCED-4997-B846-00C3A1705859Q37077352-18CB877A-1056-406D-8113-B708846CFF00Q37151698-AE5C360E-8420-403B-814D-84E562A1802EQ37233236-C5259EE3-456D-4D6A-AFB3-C9CC2BB33973Q37246360-30D11975-8337-43A5-9B06-E21286B77CB7Q37280744-594B1E89-81F5-415C-ADDD-E812449971E5Q37389544-C400653E-0115-4570-BFD8-91ABCD93ECE4Q37447344-0534A2D9-90CF-4A65-9858-D094FEB20509Q37603330-3109ED7D-9970-4897-8BE1-2E1574930685Q37934964-7D8F3D86-1FEF-4890-96A5-AAD4364A9746Q38028808-7B7F65B4-4981-4949-B551-43C9C643BF8AQ38110232-AEC66D92-B5B8-4CA0-840C-DCAA67A989FAQ38113738-0C7D77D4-652D-41F7-8DDC-7BED8D03945DQ38173985-BECA2825-C708-49DA-8A5A-1E9C57748279Q38534837-D675741C-A711-4731-B9FB-466A40AB6D98
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Minimal residual disease in leukaemia patients.
@ast
Minimal residual disease in leukaemia patients.
@en
Minimal residual disease in leukaemia patients.
@nl
type
label
Minimal residual disease in leukaemia patients.
@ast
Minimal residual disease in leukaemia patients.
@en
Minimal residual disease in leukaemia patients.
@nl
prefLabel
Minimal residual disease in leukaemia patients.
@ast
Minimal residual disease in leukaemia patients.
@en
Minimal residual disease in leukaemia patients.
@nl
P2093
P1433
P1476
Minimal residual disease in leukaemia patients.
@en
P2093
J F San Miguel
J J van Dongen
T Szczepański
V H van der Velden
P304
P356
10.1016/S1470-2045(00)00418-6
P577
2001-07-01T00:00:00Z